









Press release

Laclarée raises 3.5 m€ for its Seed round, welcoming a new shareholder, RIMONCI, one of the best investor specialized in vison-care, alongside with its historical investors, UI-Investissement, High-Tech GründerFonds (HTGF) and Business Angels.

Laclarée gets financial support from Rimonci, a vision care Venture fund, UI-Investissement (former Kreaxi, France), High-Tech GründerFonds HTGF (Germany) and highly qualified Business Angels. The total amount raised in equity, 3.5 m€, will complement the support of the EIC accelerator (Europe) 2.5m€ financing of the company. Laclarée develops adaptive (autofocussing) eyeglasses for presbyopia correction. This Seed investment will help developing the first commercial product of Laclarée, by mid-2026.

Lyon, France. 2025, January 28th

With an exclusive solution that recreates the eyes' natural autofocus, Laclarée redefines the visual experience.

After the age of 45, everyone (that is 2b people worldwide) gets hit by presbyopia and it worsens with age, making it impossible to read, use a laptop or a smartphone or any activity requiring close vision without a dedicated solution. All existing solutions bring compromises and difficulties, even the most advanced ones like progressive lenses. Presbyopia is a natural phenomenon due to eye's ageing, but it becomes a handicap for a significant number of people unfitted to the existing solutions, leading to visual fatigue, headaches, eyestrain, postural pains, musculoskeletal problems and trouble in realizing critical activities requiring multi-tasking or multiple targets.

Laclarée is developing autofocusing eyeglasses for the millions of people affected by presbyopia, based on an opto-fluidic technology protected by its patented worldwide portfolio. The revolutionary eyeglasses feature variable focus lenses driven by actuating units in each temple and distance sensors. With the combination of those three bricks, the optical correction of the eyeglasses is real-time adapted to the distance between the user and the object he or she is looking at. Laclarée lenses also include the necessary refractive corrections, hyperopia, astigmatism, and myopia, according to the patient prescription.

Laclarée has performed many wearers tests, proving the benefits of the product: retrieving natural focusing. A lot of people prefer to wear Laclarée lenses. Laclarée is now considered ahead of the race for e-focus as it is recognized by leading industry experts.

Thanks to this unique breakthrough, the brand offers fluid, intuitive and effortless vision, adapted to every moment of life. At a time when traditional solutions are struggling to meet the expectations of a world in perpetual motion, Laclarée offers a clear, modern response: discreet yet powerful technology that transforms visual challenges into natural experiences.











"We are happy that Rimonci joins our current investors UI-Investissement and HTGF, confirming our global approach of the market. In the past years, Laclarée team has worked hard to seek the wearers feedback and expectations, and the result has turned positive: many presbyopes want to wear Laclarée eyeglasses as their visual correction mean. This Seed round will be key for Laclarée to offer to these customers the first commercial autofocussing eyeglass pair." said Bruno BERGE, CEO and founder of the company. "We are thrilled to support Laclarée to bring its breakthrough technology to new markets, setting a new standard for presbyopia correction worldwide. This investment aligns with Rimonci's mission to back transformative technologies in vision care that address unmet medical needs for better vision and insight." mentions Richel LIU, founder and manager of RIMONCI CAPITAL.

About Laclarée

Laclarée was founded in 2016 by Bruno Berge, physicist and entrepreneur, joined by a team gathering high-tech skills in optics, electronics, materials and microfluidics. The company has labs in Lyon, partnership with INL (Institut des Nanotechnologies de Lyon), and is supported by Bpifrance, Region Auvergne-Rhone-Alpes and Europe. Laclarée has been awarded of many prizes, including i-LAB, i-NOV in France, and more recently by EIC accelerator. Laclarée is supported by top-class Business Angels specialists of vision care.

For more material, please contact us.

Press contact:

bruno.berge@laclaree-vision.com

Laclarée, 11 Avenue Albert Einstein, 69100 Villeurbanne, France

Phone: +33 633 42 38 27 www.laclaree-vision.com

https://www.linkedin.com/company/laclaree/

About RIMONCI

Contact: Richel Liu (Richel@rimonci.com https://rimonci.com/)

Rimonci Capital is a specialized venture capital fund focused on vision care, particularly ophthalmology and optometry. Established in 2016, Rimonci is dedicated to empowering transformative advancements for better vision and insight.

About UI Investissement

Contact: Laurent Maillard (+33 660 59 77 07 | www.ui-investissement.fr - laurent.maillard@ui-investissement.fr)

UI Investissement is an independent management company specializing in the development of unlisted French companies. It manages around €1.5 billion in assets and invests with more than 300 portfolio companies in sectors that are essential to society, such as healthcare, agri-business, services and industry. The investment teams dedicated to innovation capital deploy funds that enable the emergence of innovative projects and high-potential disruptive technologies in the tech and healthcare sectors by providing financing, advice and support. Expansion and buyout capital, the historical core of











UI's business, accounts for more than half of assets under management, enabling more than 50 companies to benefit from the operational expertise and methodological tools developed by UI. Finally, UI also invests in projects aimed at strengthening economic initiatives in local areas. UI currently has more than 80 employees and more than 10 regional offices in Besançon, Clermont-Ferrand, Dijon, Lille, Limoges, Lyon, Nantes, Orléans, Reims, Rennes, Strasbourg, in addition to its teams in Paris.

About High-Tech Gründerfonds (HTGF)

Contact: Dr. Gernot Berger,

G.Berger@htgf.de

High-Tech Gründerfonds, Schlegelstraße 2, 53113 Bonn, Germany

HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more than 770 start-ups and achieved over 190 successful exits.

<u>Fund investors</u> in the public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital as well as 45 companies and family offices. For more information, please visit <u>HTGF.de</u> or follow us on <u>LinkedIn</u>.